Veradermics, Incorporated
MANE
NYSE·Healthcare·Biotechnology·Mkt cap $4.1B
$98.51
▲ +0.78%
P/E
-45.35
Mkt Cap
$4.1B
52-Wk Range
$32.00–$131.24
52-Week Range
$32.00 - $131.24
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 158.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary dissolvable microarray patch technology platform
- Non-hormonal, oral treatment approach for pattern hair loss
- Focus on underserved pediatric dermatology populations
- Diverse pipeline reducing single-product risk
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Clinical trial progression and regulatory approvals for VDPHL01
Value
Deep value opportunity - significant discount to sector peers
Momentum
Stable
-3.4% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MANE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 10, 2026
AUG 11, 2026
Reported EPS of -$0.58 vs -$0.65 consensus (+10.4% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+10.4%
Revenue trend · last 4Q
—
—
—
—
Q4 24
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
Margins · last 4Q
No margin history available.
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Jul 16, 2026
vs Industry
How MANE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.